Indaptus Therapeutics is trading 6.1% up at $2.79 following several volatile sessions and a recent market rebound.
- The move appears driven by broader risk-on sentiment in U.S. equities rather than a new company-specific catalyst.
- There are no fresh headlines, earnings releases, or clinical trial updates reported for the company this morning.